Logo

To offer you a better experience, this site uses cookies, including those of third parties. To find out more and manage your preferences, consult the cookie policy

Get updates

When you see uveal melanoma, you can't afford to wait

Watch brief video

Though it may start as an isolated tumor of the eye, uveal melanoma (UM) metastasizes in up to 50% of patients,
becoming a systemic disease.1

As metastatic UM (mUM) runs its course, treatment options are limited and patients face a median survival of up to 12 months.2 So, when you see mUM, think fast.

Learn more

Presentation and symptoms, risk factors and management

Get details

Intrinsic differences between UM and cutaneous melanoma (CM)

See resources

Clinical perspectives and resources for patients and caregivers

    References:
  1. Carvajal RD, Schwartz GK, Tezel T, Marr B, Francis JH, Nathan PD. Metastatic disease from uveal melanoma: treatment options and future prospects. Br J Ophthalmol. 2017;101(1):38-44.
  2. Nathan P, Cohen V, Coupland S, et al. Uveal melanoma UK national guidelines. Eur J Cancer. 2015;51(16):2404-2412.